Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva b.v. - metotrexat - injektionsvätska, lösning i förfylld spruta - 7,5 mg - metotrexat 7,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - mykofenolatmofetil - kapsel, hård - 250 mg - mykofenolatmofetil 250 mg aktiv substans; propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

2care4 aps - mykofenolatmofetil - kapsel, hård - 250 mg - natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne; mykofenolatmofetil 250 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

intas pharmaceuticals limited - kapecitabin - filmdragerad tablett - 500 mg - laktos (vattenfri) hjälpämne; kapecitabin 500 mg aktiv substans - kapecitabin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pharos - pharmaceutical oriented services ltd - kapecitabin - filmdragerad tablett - 500 mg - kapecitabin 500 mg aktiv substans - kapecitabin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

gp pharm - oxaliplatin - pulver till infusionsvätska, lösning - 5 mg/ml - oxaliplatin 5 mg aktiv substans; laktosmonohydrat hjälpämne - oxaliplatin

Europeiska unionen - svenska - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatit, atopisk - andra dermatologiska preparat - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunsuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Europeiska unionen - svenska - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - imidakloprid, moxidektin - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme). det veterinärmedicinska läkemedlet kan användas som en del av en behandlingsstrategi för loppalergidermatit (fad).  for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).  for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis). det veterinärmedicinska läkemedlet kan användas som en del av en behandlingsstrategi för loppalergidermatit (fad).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - metotrexat - koncentrat till infusionsvätska, lösning - 100 mg/ml - metotrexat 100 mg aktiv substans - metotrexat